Depression News and Research

Latest Depression News and Research

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

Tips for healthy living for the year ahead

Whether you are a vegetarian, vegan, carnivore or pescetarian, vegetables should be a central part of your diet. Often referred to as a "protective food," dark green foods provide essential vitamins and nutrients to your body that protect you from many of life's worst diseases.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

ARNMD meeting examines psychological and neurological aspects of PTSDs and traumatic brain injuries

War is hell, as the old saying goes -- with loss of life and limb, destruction of infrastructure and the environment, and devastating costs. Recent biomedical research has shed light on another pernicious consequence of military conflict: psychological and neurological conditions like post-traumatic stress disorder and traumatic brain injury. At the same time, researchers have worked to uncover some of the motives and meanings of war.

17 Dec 2009

HFU increases mortality among diabetics, says report

Cardium Therapeutics today reported on recent clinical findings published in the December issue of Diabetes Care showing an increase in mortality in diabetic patients with a history of foot ulcer (HFU) compared with diabetic patients without HFU and with non-diabetic patients.

17 Dec 2009

HHS Secretary Kathleen Sebelius announces $27 million to help older individuals with chronic conditions

HHS Secretary Kathleen Sebelius has announced the availability of $27 million to help older individuals with chronic conditions to improve their health and reduce their use of costly medical care.

17 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

HealthInsight and HealthMedia join to deliver Internet-based Digital Coaching solutions

HealthInsight, provider of the only value-based health care administration platform, today announced a partnership with HealthMedia, Inc., a Johnson & Johnson company, to deliver Internet-based Digital Coaching™ solutions focused on lifestyle and behavioral change.

16 Dec 2009

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

Binghamton University psychologist to provide new weapons to fight against childhood depression

Research by Binghamton University psychologist Brandon Gibb could provide new weapons for the fight against childhood depression. Working with colleagues around the country, he hopes to identify the causes of mental-health problems in kids and define trajectories of risk for depression.

16 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.

15 Dec 2009

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Women with suspected coronary artery disease (CAD) who report taking antidepressant and anti-anxiety medications have an increased risk of cardiovascular events, including heart attacks and strokes, and death compared to women not taking these medications, according to researchers at the Uniformed Services University of the Health Sciences (USU).

15 Dec 2009

Demystifying Psychiatry: A resource for patients and families

Psychiatric disorders are underdiagnosed, poorly treated and highly stigmatized, according to psychiatrists Charles F. Zorumski, M.D., and Eugene H. Rubin, M.D., Ph.D. So these Washington University physicians have written a book to address those problems.

15 Dec 2009

Postmenopausal women who take antidepressants face increased risk for stroke and death

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women's Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

14 Dec 2009

Cultural activities may improve health and protect against depression

If you paint, dance or play a musical instrument - or just enjoy going to the theatre or to concerts -- it's likely that you feel healthier and are less depressed than people who don't, a survey of nearly 50,000 individuals from all socio-economic backgrounds from a county in mid-Norway shows.

14 Dec 2009

Eggs of marine animals is the best dietary source of Omega 3 fatty acids

The roe of hake, lumpsucker and salmon is the best dietary source of Omega 3, according to a study carried out by researchers at the University of Almer-a (UAL). The scientists analysed the eggs, or roe, of 15 marine animals, and found all of these contained high levels of these fatty acids, which are essential to the human body.

14 Dec 2009

Depression News and Research

Latest Depression News and Research

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Tips for healthy living for the year ahead

ASA offers practical ways for sufferers to take active role in treatment of pain

ARNMD meeting examines psychological and neurological aspects of PTSDs and traumatic brain injuries

HFU increases mortality among diabetics, says report

HHS Secretary Kathleen Sebelius announces $27 million to help older individuals with chronic conditions

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

HealthInsight and HealthMedia join to deliver Internet-based Digital Coaching solutions

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Binghamton University psychologist to provide new weapons to fight against childhood depression

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Demystifying Psychiatry: A resource for patients and families

Postmenopausal women who take antidepressants face increased risk for stroke and death

Cultural activities may improve health and protect against depression

Eggs of marine animals is the best dietary source of Omega 3 fatty acids

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Depression News and Research

Latest Depression News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in